Biotricity to Announce Continued Growth in Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th
Rhea-AI Summary
Biotricity (OTCQB:BTCY) will host its Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11, 2026 at 4:30 PM ET. The company reported continued revenue growth and achieved positive EBITDA, and management will provide remarks followed by a Q&A.
Webcast access begins 15 minutes early; a replay will be available through February 25, 2026 at 11:59 PM ET.
Positive
- Announced positive EBITDA for fiscal third quarter
- Scheduled investor call on Feb 11, 2026 with CEO and CFO remarks
- Replay available through Feb 25, 2026, improving investor access
Negative
- None.
News Market Reaction
On the day this news was published, BTCY gained 10.68%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
BTCY is up 2.27% while peers show mixed moves: GTHP up 41.62%, PCHM up 0.27%, PYNKF down 4.09%, PETV down 1.74%, and CSDX flat. This points to a stock-specific reaction to the earnings-date news rather than a broad sector shift.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 14 | Q2 FY2026 results | Positive | -9.1% | Reported Q2 FY2026 revenue growth and margin expansion with smaller net loss. |
| Nov 07 | Earnings call date | Neutral | -3.4% | Announced date and logistics for Q2 FY2026 results and business update call. |
| Sep 09 | Distribution partnership | Positive | -14.1% | Collaboration expanding Bioheart access to over 70M FSA and HSA users. |
| Sep 03 | Platform expansion | Positive | +15.7% | Expanded cardiac monitoring platform to integrate ECG from consumer wearables. |
| Aug 14 | Q1 FY2026 results | Positive | +0.0% | Strong Q1 with positive EBITDA, revenue growth, and improved gross margins. |
Positive operational and growth updates have not consistently translated into positive next-day moves, with several constructive releases followed by flat or negative reactions.
Over the past six months, Biotricity has repeatedly highlighted growth and improving profitability. Q1 FY2026 results on Aug 14 featured first-ever positive EBITDA and 21% revenue growth, yet the stock was unchanged. Q2 FY2026 results on Nov 14 showed revenue of $3.9M and margin expansion, but shares fell 9.06%. Product and partnership news, such as the B-Secur platform expansion on Sep 3, drew a 15.66% gain, while a major collaboration on Sep 9 saw a 14.08% drop. Today’s call announcement fits a pattern of recurring updates on growth and efficiency.
Market Pulse Summary
The stock surged +10.7% in the session following this news. A strong positive reaction aligns with Biotricity’s messaging around revenue growth, margin strength, and positive EBITDA, as referenced in this call announcement. Historically, some upbeat financial updates still saw negative or flat moves, such as the -9.06% reaction after Q2 FY2026 results and a flat response to Q1’s first positive EBITDA. Investors would have weighed this new indication of continued progress against prior volatility and the company’s existing financial and regulatory disclosures.
Key Terms
ebitda financial
technology-as-a-service (taas) technical
webcast technical
AI-generated analysis. Not financial advice.
Company continues to drive Revenue Growth, Margin Strength, Operational Efficiency, and continued positive EBITDA
REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th, at 4:30 PM Eastern Time. The Company announces continued progress in its financial performance, including achieving a positive EBITDA and continued growth. Biotricity’s Founder and CEO, Dr. Waqaas Al-Siddiq, and CFO, John Ayanoglou, will deliver remarks followed by a Q&A section to address questions from investors.
Event: Biotricity Fiscal 2026 Third Quarter Financial Results and Business Update Call
Date: Wednesday, February 11, 2026
Time: 4:30 PM ET (1:30 PM PT)
Toll Free: 1-877-269-7751
International: 1-201-389-0908
Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1751341&tp_key=10b4deecf5
Investors can begin accessing the webcast 15 minutes before the call, where an operator will register your name and organization. The call will be in listen-only mode.
A replay of the call will be available approximately 3 hours after the live call via the Investors section of the Biotricity website at https://biotricity.com/investors/.
Toll Free Replay Number: 1-844-512-2921
International: 1-412-317-6671
Replay Access ID: 13758520
Expiration: Wednesday, February 25, 2026 at 11:59 PM ET
About Biotricity Inc.
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.
To learn more about the benefits of using Biotricity’s solutions, click here and here. For consumers interested in continuous, 24/7 clinical-grade monitoring at home with Bioheart, click here.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” “project,” or “goal” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. There cannot be any assurance that the Company will ever become profitable. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Contacts:
Investor relations:
Biotricity Investor Relations
Investors@biotricity.com
Media
Website
Facebook
Instagram
LinkedIn
YouTube
FAQ
When will Biotricity (BTCY) present its Fiscal 2026 Q3 results?
How can investors access the Biotricity (BTCY) Q3 2026 webcast and replay?
What key financial outcome did Biotricity (BTCY) report for fiscal Q3 2026?
Who will speak on the Biotricity (BTCY) Q3 2026 earnings call?
What is the format and registration process for Biotricity (BTCY) Q3 2026 call?
